Experts share insight on the evolving treatment armamentarium for myeloproliferative neoplasms.
EP. 1: A Brief Overview of Myeloproliferative Neoplasms
Expert Stephen Oh, MD, PhD, provides a broad overview of the myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, and myelofibrosis.
EP. 2: Making a Differential Diagnosis of Polycythemia Vera
Shared insight on making a differential diagnosis of polycythemia vera and properly risk-stratifying patients who present with this disease.
EP. 3: Treatment Armamentarium for Polycythemia Vera
Pankit Vachhani, MD, provides a comprehensive overview of approved agents used to manage patients with polycythemia vera.
EP. 4: Polycythemia Vera: Ruxolitinib Use and Goals of Therapy
A brief discussion on the role of ruxolitinib in the management of polycythemia vera, followed by a review of goals of therapy in this setting.
EP. 5: Making a Differential Diagnosis of Myelofibrosis
Shared insight on the differential diagnosis of myelofibrosis, including advice for identifying primary versus secondary disease.
EP. 6: Addressing the Challenges in Diagnosing MF
Reflections on the predominant challenges one may face while making a differential diagnosis of myelofibrosis.
EP. 7: Risk Assessment and Staging of Myelofibrosis
Experts focus on how best to risk stratify and stage myelofibrosis using appropriate diagnostic tools and workup.
EP. 8: Myelofibrosis: Observation and Triggers to Initiate Therapy
Expert Pankit Vachhani, MD, breaks down best practices in observation and dictates when it is best to initiated therapy for myelofibrosis.
EP. 9: Factors in Selecting Therapy for Myelofibrosis
Stephen Oh, MD, PhD, highlights the role of transplant in myelofibrosis before Ruben Mesa, MD, discusses factors in selecting systemic therapy.
EP. 10: Historical Approaches to the Management of MF
A brief review of the historical use of systemic therapy in patients who present with myelofibrosis.
EP. 11: Use of Ruxolitinib in Myelofibrosis
Expert perspectives on the role of ruxolitinib in patients who require systemic therapy for myelofibrosis.
EP. 12: Myelofibrosis: Use of Fedratinib and Pacritinib Therapy
Shared insight on the respective roles of fedratinib and pacritinib in patients diagnosed with myelofibrosis.
EP. 13: Selection and Management of JAK Inhibitor Therapy in MF
Taking into account the three JAK inhibitors, ruxolitinib, fedratinib, and pacritinib, experts reflect on the appropriate use of each agent in myelofibrosis.
EP. 14: Myelofibrosis: Patient Monitoring and Triggers to Change Therapy
Expert perspectives on monitoring patients receiving therapy for myelofibrosis, with additional considerations for when it is appropriate to switch therapy.
EP. 15: Novel Agents in the Pipeline for Myelofibrosis
A comprehensive review of novel agents currently under investigation with a potential role in the myelofibrosis treatment landscape.
EP. 16: Myelofibrosis: Novel Combination Strategies
Focusing on novel combination strategies, experts review clinical trial data and consider where these regimens may fall in the myelofibrosis treatment armamentarium.
EP. 17: Clinical Pearls for the Management of Myelofibrosis
Closing out their discussion on myelofibrosis, experts provide practical advice for identifying and managing patients in real-world practice.
DK210 (EGFR) Induces Immune Response Without Increased CRS or Regulatory T Cells in Solid Tumors
Siglec-15 Represents Potential Therapeutic Target in NSCLC, Other Solid Tumors
Radiomic Biomarkers Predict Response in Lung and Liver Uveal Melanoma Metastases
BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors